## ELV: Elevance Health, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.88 indicates fundamental undervaluation.

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($339.70)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Elevance Health appoints healthcare executive Amy Schulman to board By Investing.com**
- Source: Investing.com UK | 20251210T220807 | Bullish | Relevance: 99%
-  Elevance Health announced the appointment of Amy Schulman, a healthcare executive and venture capital leader, to its board of directors, effective January 12, 2026. Schulman will serve on the company's Audit and Finance Committees. This appointment aligns with Elevance Health's board refreshment strategy to ensure diverse and independent leadership.

**2. Bronstein, Gewirtz & Grossman, LLC Encourages Elevance Health, Inc. (ELV) Stockholders to Inquire about Securities Investigation**
- Source: WRBL | 20251211T160758 | Neutral | Relevance: 99%
-  Bronstein, Gewirtz & Grossman, LLC has announced an investigation into potential corporate wrongdoing by Elevance Health, Inc. (NYSE:ELV) and its officers/directors. The firm is encouraging stockholders who purchased Elevance securities prior to April 18, 2024, and continue to hold them, to inquire about the securities investigation. The investigation aims to determine if there are grounds for a class action lawsuit, with no cost to investors unless the firm is successful in recovering funds.

**3. Elevance Health appoints healthcare executive Amy Schulman to board**
- Source: Investing.com | 20251210T220810 | Bullish | Relevance: 99%
-  Elevance Health (NYSE:ELV) has appointed healthcare executive and venture capital leader Amy Schulman to its board of directors, effective January 12, 2026. Schulman, currently a Managing Partner at Polaris Partners, will serve on the companyâ€™s Audit and Finance Committees. This appointment aligns with Elevance Health's strategy for diverse and independent leadership.

**4. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elevance Health, Inc. (ELV) and Encourages Investors to Learn More About the Investigation**
- Source: KTLA | 20251209T160812 | Neutral | Relevance: 99%
-  Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Elevance Health, Inc. (NYSE:ELV). The firm encourages investors who purchased Elevance securities prior to April 18, 2024, and still hold them, to contact them for more information and to assist in the investigation. The investigation aims to determine if Elevance officers and/or directors engaged in misconduct.

**5. Elevance Health Inc. stock outperforms competitors on strong trading day**
- Source: MarketWatch | 20251211T163000 | Bullish | Relevance: 99%
-  Shares of Elevance Health Inc. (ELV) rose 5.62% to $360.22 on Thursday, outperforming competitors and contributing to a strong trading day for the stock market. The S&P 500 Index and the Dow Jones Industrial Average also saw gains. This marks the second consecutive day of gains for Elevance Health Inc. stock.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-26 | TD Cowen | $400 | $380 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-26 | TD Cowen | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.6%)
- Blackrock Inc.: 9.2% (+0.6%)
- State Street Corpora: 4.7% (-2.1%)
- Wellington Managemen: 3.0% (+4.8%)
- Price (T.Rowe) Assoc: 2.6% (-27.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +7.4% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.88 indicates undervaluation relative to growth. Analyst sentiment positive (1 raises, avg +5%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $81.1B |
| Beta | 0.53 |
| 52W Range | $273.71 - $458.75 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.88 |
| Forward P/E | 13.2 |
| Current P/E | 12.0 |
| YoY Growth | -9.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -0.8% to 6.6% (+7.4% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 83rd percentile. MRS_5 at 6.4% confirms short-term momentum alignment. AM_20 at 8.9% shows strong absolute momentum above own 20MA. Outperforming sector by 8.9pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (2.58), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 6.58% (CS: 84) | Strong |
| RSI_14 | 69.8 | Neutral |
| MACD Histogram | 2.58 | Bullish |
| vs SMA20 | 1.088x | Above |
| vs SMA50 | 1.074x | Above |
| vs SMA200 | 1.007x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $360.22
- **Stop Loss:** $339.70 (5.7% risk)
- **Target:** $401.26 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 67
- **Position Value:** $24,134.74
- **Portfolio %:** 24.13%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-01-22 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.94 | $6.03 | +22.0% |
| 2025Q2 | $8.96 | $8.84 | -1.4% |
| 2025Q1 | $11.48 | $11.97 | +4.3% |
| 2024Q4 | $3.85 | $3.84 | -0.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*